The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Alexza Pharmaceuticals Inc | COM | 015384100 | 1,774 | 374,999 | SH | SOLE | 374,999 | 0 | 0 | ||
Anacor Pharmaceuticals Inc | COM | 032420101 | 25,942 | 1,545,999 | SH | SOLE | 1,545,999 | 0 | 0 | ||
BioCryst Pharmaceuticals Inc | COM | 09058V103 | 13,333 | 1,754,356 | SH | SOLE | 1,754,356 | 0 | 0 | ||
Biodel Inc | COM | 09064M105 | 2,728 | 1,196,492 | SH | SOLE | 1,196,492 | 0 | 0 | ||
Chelsea Therapeutics International Ltd | COM | 163428105 | 7,545 | 1,701,170 | SH | SOLE | 1,701,170 | 0 | 0 | ||
DBV Technologies | COM | F2927N109 | 7,176 | 480,000 | SH | SOLE | 480,000 | 0 | 0 | ||
Dyax Corp | COM | 26746E103 | 19,493 | 2,586,980 | SH | SOLE | 2,586,980 | 0 | 0 | ||
GW Pharmaceuticals | COM | 36197T103 | 29,052 | 699,376 | SH | SOLE | 699,376 | 0 | 0 | ||
Heron Therapeutics | COM | 00202J203 | 9,862 | 21,914,700 | SH | SOLE | 21,914,700 | 0 | 0 | ||
Hyperion Therapeutics Inc | COM | 44915N101 | 2,209 | 109,271 | SH | SOLE | 109,271 | 0 | 0 | ||
Ironwood Pharmaceuticals Inc | COM | 46333X108 | 20,898 | 1,800,000 | SH | SOLE | 1,800,000 | 0 | 0 | ||
Keryx Biopharmaceuticals Inc | COM | 492515101 | 12,954 | 1,000,273 | SH | SOLE | 1,000,273 | 0 | 0 | ||
Neurocrine Biosciences Inc | COM | 64125C109 | 6,490 | 694,903 | SH | SOLE | 694,903 | 0 | 0 | ||
Ocera Therapeutics | COM | 67552A108 | 9,141 | 703,730 | SH | SOLE | 703,730 | 0 | 0 | ||
TESARO Inc | COM | 881569107 | 3,890 | 137,749 | SH | SOLE | 137,749 | 0 | 0 | ||
TherapeuticsMD Inc | COM | 88338N107 | 4,410 | 846,500 | SH | SOLE | 846,500 | 0 | 0 | ||
Vanda Pharmaceuticals Inc | COM | 921659108 | 8,924 | 719,075 | SH | SOLE | 719,075 | 0 | 0 |